[Intravenous iron during predialysis period improves anemia management and cardiovascular parameters in incident hemodialysis patients].

[1]  G. Parati,et al.  The use of echocardiography in observational clinical trials: the EURECA-m registry. , 2013, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[2]  Yong Yang,et al.  Multidirectional myocardial systolic function in hemodialysis patients with preserved left ventricular ejection fraction and different left ventricular geometry. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[3]  D. Joly,et al.  [Prepare: cross-sectional study on management of chronic kidney disease by nephrologists before dialysis in France]. , 2012, Nephrologie & therapeutique.

[4]  Spencer E. Harpe,et al.  Utilization Patterns of IV Iron and Erythropoiesis Stimulating Agents in Anemic Chronic Kidney Disease Patients: A Multihospital Study , 2012, Anemia.

[5]  Shu-cheng Chen,et al.  Prevalence of arteriovenous fistulas in incident hemodialysis patients: correlation with patient factors that may be associated with maturation failure. , 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[6]  C. Anderson,et al.  Cardiovascular risk management in chronic kidney disease in general practice (the AusHEART study). , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[7]  K. Aonuma,et al.  Effects of anemia correction by erythropoiesis-stimulating agents on cardiovascular function in non-dialysis patients with chronic kidney disease. , 2012, International heart journal.

[8]  H. Uno,et al.  Stroke in Patients With Type 2 Diabetes Mellitus, Chronic Kidney Disease, and Anemia Treated With Darbepoetin Alfa: The Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT) Experience , 2011, Circulation.

[9]  J. Rottembourg,et al.  Faisabilité de la stratégie d’administration de la darbepoetin alfa tous les 15 jours : expérience 2005–2007 d’un centre de dialyse , 2011 .

[10]  Ajay K. Singh.  Is there a deleterious effect of erythropoietin in end-stage renal disease? , 2011, Kidney international.

[11]  David M Kent,et al.  Predicting mortality in incident dialysis patients: an analysis of the United Kingdom Renal Registry. , 2011, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[12]  S. Briançon,et al.  Predialysis therapeutic care and health-related quality of life at dialysis onset (The pharmacoepidemiologic AVENIR study) , 2011, Health and quality of life outcomes.

[13]  D. Gozzard.  When is high-dose intravenous iron repletion needed? Assessing new treatment options , 2011, Drug design, development and therapy.

[14]  K. Eckardt.  Chronic kidney disease: Are elevated doses of ESAs associated with adverse outcomes? , 2010, Nature Reviews Nephrology.

[15]  H. Uno,et al.  Erythropoietic response and outcomes in kidney disease and type 2 diabetes. , 2010, The New England journal of medicine.

[16]  D. Coyne.  It's time to compare anemia management strategies in hemodialysis. , 2010, Clinical journal of the American Society of Nephrology : CJASN.

[17]  Yang Qiu,et al.  Trends in patient characteristics and first-year medical costs of older incident hemodialysis patients, 1995-2005. , 2010, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[18]  I. Macdougall.  Iron supplementation in the non-dialysis chronic kidney disease (ND-CKD) patient: oral or intravenous? , 2010, Current medical research and opinion.

[19]  R. Garrick.  Comparative Mortality Risk of Anemia Management Practices in Incident Hemodialysis Patients , 2010 .

[20]  P. Ponikowski,et al.  Ferric carboxymaltose in patients with heart failure and iron deficiency. , 2009, The New England journal of medicine.

[21]  S. Solomon,et al.  A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. , 2009, The New England journal of medicine.

[22]  P. Parfrey,et al.  Erythropoietin therapy and left ventricular mass index in CKD and ESRD patients: a meta-analysis. , 2009, Clinical journal of the American Society of Nephrology : CJASN.

[23]  K. Kalantar-Zadeh,et al.  Intravenous iron versus erythropoiesis-stimulating agents: friends or foes in treating chronic kidney disease anemia? , 2009, Advances in chronic kidney disease.

[24]  C. Kovesdy.  Iron and clinical outcomes in dialysis and non-dialysis-dependent chronic kidney disease patients. , 2009, Advances in chronic kidney disease.

[25]  K. Kalantar-Zadeh,et al.  Hemoglobin variability in anemia of chronic kidney disease. , 2009, Journal of the American Society of Nephrology : JASN.

[26]  R. Foley,et al.  Parenteral iron use: possible contribution to exceeding target hemoglobin in hemodialysis patients. , 2009, Clinical journal of the American Society of Nephrology : CJASN.

[27]  A. Martín-Malo,et al.  Baseline characteristics of an incident haemodialysis population in Spain: results from ANSWER—a multicentre, prospective, observational cohort study , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[28]  S. Soroka,et al.  Health-related quality of life and hemoglobin levels in chronic kidney disease patients. , 2009, Clinical journal of the American Society of Nephrology : CJASN.

[29]  P. Aljama,et al.  Factors that condition the response to erythropoietin in patients on hemodialysis and their relation to mortality. , 2008, Kidney international. Supplement.

[30]  C. Stehman-Breen,et al.  Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[31]  I. C. Macdougall.  Anaemia of chronic kidney disease , 2007 .

[32]  R. Balkrishnan,et al.  Undertreatment of anemia in patients with chronic kidney disease in the United States: analysis of national outpatient survey data. , 2007, Clinical therapeutics.

[33]  I. Macdougall,et al.  OPTA-therapy with iron and erythropoiesis-stimulating agents in chronic kidney disease , 2007 .

[34]  Brenda W Gillespie,et al.  Predictors of early mortality among incident US hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). , 2006, Clinical journal of the American Society of Nephrology : CJASN.

[35]  V. Prasad.  Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease , 2007 .

[36]  H. Burger,et al.  Normalization of hemoglobin level in patients with chronic kidney disease and anemia. , 2006, The New England journal of medicine.

[37]  R. Foley,et al.  Hemoglobin level variability: associations with comorbidity, intercurrent events, and hospitalizations. , 2006, Clinical journal of the American Society of Nephrology : CJASN.

[38]  J. Wauters,et al.  Phenotypic and genotypic risk factors for cardiovascular events in an incident dialysis cohort. , 2006, Kidney international.

[39]  Saul Nurko,et al.  Anemia in chronic kidney disease: causes, diagnosis, treatment. , 2006, Cleveland Clinic journal of medicine.

[40]  G. Mircescu,et al.  Intravenous iron supplementation for the treatment of anaemia in pre-dialyzed chronic renal failure patients. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[41]  A. Collins,et al.  Trends in intravenous iron use among dialysis patients in the United States (1994-2002). , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[42]  D. Marcelli,et al.  Risk factors and underlying cardiovascular diseases in incident ESRD patients. , 2005, Journal of nephrology.

[43]  R. Wolfe,et al.  Patterns of medication use in the RRI-CKD study: focus on medications with cardiovascular effects. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[44]  S. Aronoff,et al.  The prevalence of anemia in patients with chronic kidney disease , 2004, Current medical research and opinion.

[45]  M. Devita,et al.  Targeting higher ferritin concentrations with intravenous iron dextran lowers erythropoietin requirement in hemodialysis patients. , 2003, Clinical nephrology.

[46]  D. Silverberg.  Outcomes of anaemia management in renal insufficiency and cardiac disease. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[47]  C. Chang,et al.  Reduction in erythropoietin doses by the use of chronic intravenous iron supplementation in iron-replete hemodialysis patients. , 2002, Clinical nephrology.

[48]  D J Pennell,et al.  Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance; are they interchangeable? , 2000, European heart journal.

[49]  K. Eckardt,et al.  Does early anemia correction prevent complications of chronic renal failure? , 1999, Clinical nephrology.

[50]  A R Nissenson,et al.  The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. , 1998, The New England journal of medicine.

[51]  Perazella Ma.  Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. , 1995 .

[52]  Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Canadian Erythropoietin Study Group. , 1990, BMJ.

[53]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.